中州證券(01375.HK)提名李文強為董事
格隆匯6月9日丨中州證券(01375.HK)公吿,公司董事會於2025年6月9日收到公司董事魯智禮先生和李興佳先生提交的書面辭職報吿。魯智禮先生由於工作調整,李興佳先生由於到齡退休,均申請辭去公司第七屆董事會董事和董事會下屬專門委員會委員等一切職務。在公司股東大會選舉產生新任董事之日前,魯智禮先生與李興佳先生將繼續履行董事相關職責。
公司於2025年6月9日召開第七屆董事會第三十五次會議,提名李文強先生及馮若凡先生為公司第七屆董事會董事,當選董事後兼任董事會發展戰略委員會委員,任期自股東於股東大會批准之日起至第七屆董事會換屆之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.